ATE366121T1 - Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie - Google Patents

Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie

Info

Publication number
ATE366121T1
ATE366121T1 AT99903557T AT99903557T ATE366121T1 AT E366121 T1 ATE366121 T1 AT E366121T1 AT 99903557 T AT99903557 T AT 99903557T AT 99903557 T AT99903557 T AT 99903557T AT E366121 T1 ATE366121 T1 AT E366121T1
Authority
AT
Austria
Prior art keywords
serum
cancer therapy
systemic administration
lipid particles
stable plasmid
Prior art date
Application number
AT99903557T
Other languages
English (en)
Inventor
Ian Maclachlan
Roger Graham
Original Assignee
Protiva Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27535971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366121(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protiva Biotherapeutics Inc filed Critical Protiva Biotherapeutics Inc
Application granted granted Critical
Publication of ATE366121T1 publication Critical patent/ATE366121T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99903557T 1998-02-03 1999-02-03 Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie ATE366121T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7359898P 1998-02-03 1998-02-03
US8691798P 1998-05-27 1998-05-27
US10142998P 1998-09-22 1998-09-22
US11238498P 1998-12-14 1998-12-14
US24310299A 1999-02-02 1999-02-02

Publications (1)

Publication Number Publication Date
ATE366121T1 true ATE366121T1 (de) 2007-07-15

Family

ID=27535971

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99903557T ATE366121T1 (de) 1998-02-03 1999-02-03 Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie

Country Status (7)

Country Link
EP (1) EP1053023B2 (de)
JP (1) JP2002502831A (de)
AT (1) ATE366121T1 (de)
AU (1) AU749881B2 (de)
CA (2) CA2321837C (de)
DE (1) DE69936444T3 (de)
WO (2) WO1999039740A2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2356342T3 (es) 1998-01-05 2011-04-07 The University Of Washington Mejora de transporte utilizando agentes de alteración de membrana.
WO2002100431A1 (en) * 2001-06-08 2002-12-19 The Forth Military Medical University A pharmaceutical kit comprising anti-human seminal plasma protein single chain antibody/human carboxypeptidase fusion protein and prodrug
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
WO2003093303A1 (en) 2002-05-06 2003-11-13 Board Of Regents, The University Of Texas System Targeting proteins to deliver therapeutic or diagnostic reagents
EP3699172A3 (de) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
WO2018081480A1 (en) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US11338045B2 (en) 2017-03-17 2022-05-24 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
WO2018191719A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
IL324506A (en) 2018-06-18 2026-01-01 Res Inst Nationwide Childrens Hospital Adeno-associated virus vector for delivery of muscle-specific microdystrophin for the treatment of muscular dystrophy
EP3852911B1 (de) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systeme und verfahren zur herstellung von lipidnanopartikeln und liposomen
GB2600859B (en) 2019-08-14 2024-04-03 Acuitas Therapeutics Inc Improved lipid nanoparticles for delivery of nucleic acids
AU2021250814A1 (en) 2020-03-30 2022-10-13 BioNTech SE RNA compositions targeting Claudin-18.2
EP4164668A1 (de) 2020-06-15 2023-04-19 Research Institute at Nationwide Children's Hospital Adeno-assoziierte virusvektorverabreichung für muskeldystrophien
WO2025056938A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
EP4319803B1 (de) 2021-04-08 2025-11-26 Vaxthera SAS Mosaikproteinhaltige coronavirus-impstoff
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
WO2023044343A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
US20250043269A1 (en) 2021-11-03 2025-02-06 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad Precise Genome Editing Using Retrons
US20250049948A1 (en) 2021-11-16 2025-02-13 Sail Biomedicines, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
EP4436549A1 (de) 2021-11-22 2024-10-02 Sail Biomedicines, Inc. Neue ionisierbare lipide und lipidnanopartikel und verfahren zur verwendung davon
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
JP2025508332A (ja) 2022-01-27 2025-03-26 ビオンテック エスエー 単純ヘルペスウイルス抗原の送達のための薬学的組成物及び関連方法
CA3245624A1 (en) 2022-03-25 2023-09-28 Sail Biomedicines, Inc. NEW IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND THEIR METHODS OF USE
CA3255619A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
AU2023268051A1 (en) 2022-05-13 2025-01-02 BioNTech SE Rna compositions targeting hiv
WO2023230295A1 (en) 2022-05-25 2023-11-30 BioNTech SE Rna compositions for delivery of monkeypox antigens and related methods
US20250375534A1 (en) 2022-05-30 2025-12-11 BioNTech SE Complexes for delivery of nucleic acids
EP4581012A2 (de) 2022-08-31 2025-07-09 Sail Biomedicines, Inc. Neue ionisierbare lipide und lipidnanopartikel und verfahren zur verwendung davon
IL319414A (en) 2022-09-23 2025-05-01 BioNTech SE Compositions for delivering antigens at the liver level and related methods
US20260151470A1 (en) 2022-09-23 2026-06-04 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
CN120129702A (zh) 2022-10-06 2025-06-10 生物技术公司 靶向密蛋白-18.2的rna组合物
CN121127490A (zh) 2022-12-28 2025-12-12 生物技术欧洲股份公司 靶向hiv的rna组合物
AU2024266138A1 (en) 2023-05-03 2025-11-13 Manifold Biotechnologies, Inc. Methods and compositions for high-throughput protein delivery, screening, and detection
CN121038807A (zh) 2023-05-03 2025-11-28 生物技术欧洲股份公司 优化的csp变体及相关方法
WO2024228044A1 (en) 2023-05-03 2024-11-07 BioNTech SE Optimized csp variants and related methods
WO2025024324A1 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
EP4746902A2 (de) 2023-07-21 2026-05-27 BioNTech SE Zusammensetzungen zur abgabe von plasmodium-antigenen und zugehörige verfahren
EP4750488A1 (de) 2023-07-24 2026-06-03 BioNTech SE Zusammensetzungen zur abgabe von plasmodium-antigenen und zugehörige verfahren
TW202519509A (zh) 2023-08-01 2025-05-16 德商拜恩技術股份公司 可離子化硫脂質及其用途
WO2025026545A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thioplipids and uses thereof
WO2025030154A1 (en) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
AU2024316307A1 (en) 2023-08-03 2026-02-26 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
CN121866336A (zh) 2023-08-03 2026-04-14 百欧恩泰欧洲股份公司 靶向hiv的rna组合物
EP4754130A2 (de) 2023-08-03 2026-06-10 BioNTech SE Gegen hiv gerichtete rna-zusammensetzungen
WO2025054556A1 (en) 2023-09-07 2025-03-13 BioNTech SE Rna compositions for delivery of mpox antigens and related methods
CN121844046A (zh) 2023-09-11 2026-04-10 C·米库尔卡 用于递送肠促胰岛素剂的rna组合物
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
FR3155424A1 (fr) 2023-11-15 2025-05-23 BioNTech SE Compositions immunogènes contre le sars-cov-2
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025134066A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025133105A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Compositions and methods
WO2025134062A2 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025149492A1 (en) 2024-01-08 2025-07-17 BioNTech SE Rna encoding an immune inhibitory il-1 family member
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
TW202543583A (zh) 2024-03-01 2025-11-16 加拿大商阿奎特斯醫療公司 用於將治療劑包覆於脂質奈米顆粒中之材料及方法
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025213131A1 (en) 2024-04-05 2025-10-09 BioNTech SE Rna compositions for delivery of orthopox antigens and related methods
WO2025262460A1 (en) 2024-06-21 2025-12-26 BioNTech SE Lipid compositions for nucleic acid delivery
WO2026015882A1 (en) 2024-07-12 2026-01-15 BioNTech SE Hsv antigen fragments and related methods
WO2026018213A1 (en) 2024-07-18 2026-01-22 Vaxthera Sas A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
WO2026020171A2 (en) 2024-07-19 2026-01-22 Aera Therapeutics, Inc. Chimeric antigen receptor constructs
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions
WO2026057625A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having a chap domain with engineered active site
WO2026057626A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having multiple enzymatically active domains
WO2026068864A1 (en) 2024-09-30 2026-04-02 BioNTech SE Engineered ch1 and cl domains for the prevention of chain mispairing
WO2026096919A1 (en) 2024-11-01 2026-05-07 Sail Biomedicines, Inc. Novel dipepetide core lipids, lipid carriers, and methods of using thereof
WO2026119817A1 (en) 2024-12-02 2026-06-11 BioNTech SE Agents and methods for targeted delivery of immune effector cells
WO2026125590A1 (en) 2024-12-13 2026-06-18 BioNTech SE Measuring nucleic acid integrity
WO2026125598A1 (en) 2024-12-13 2026-06-18 BioNTech SE Measuring nucleic acid integrity
WO2026148356A1 (en) 2025-01-06 2026-07-09 BioNTech SE Coronavirus and influenza immunogenic combinations
WO2026150132A1 (en) 2025-01-12 2026-07-16 BioNTech SE Combination therapy comprising an rna cancer vaccine and a multispecific binding agent targeting pd-1/pd-l1 and vegf/vegfr for cancer treatment
WO2026162682A1 (en) 2025-01-29 2026-08-06 BioNTech SE Compositions for delivery of plasmodium rh5 antigens and related methods
WO2026162552A1 (en) 2025-01-31 2026-08-06 BioNTech SE Agents and methods for targeted delivery to cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
EP0452457B1 (de) * 1989-11-03 1997-08-20 Vanderbilt University Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6001644A (en) 1991-12-17 1999-12-14 The Regents Of The University Of California Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR
EP0646178A1 (de) 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
JPH09501936A (ja) * 1993-08-26 1997-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
CN1636594B (zh) 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9501052D0 (en) 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
JP4335310B2 (ja) * 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US7517858B1 (en) * 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
GB9517001D0 (en) 1995-08-18 1995-10-18 Denny William Enediyne compounds
EP0857210B1 (de) 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutische antiangiogenische zusammensetzungen und verfahren
GB9523703D0 (en) 1995-11-20 1996-01-24 Wellcome Found Enzyme prodrug thearapy
US6347397B1 (en) 1999-03-29 2002-02-12 International Business Machines Corporation System, method, and program for providing an object-oriented install architecture
US8266598B2 (en) 2008-05-05 2012-09-11 Microsoft Corporation Bounding resource consumption using abstract interpretation

Also Published As

Publication number Publication date
WO1999039740A9 (en) 1999-11-25
AU2405799A (en) 1999-08-23
WO1999039740A8 (en) 1999-09-23
CA2319468A1 (en) 1999-08-12
AU749881B2 (en) 2002-07-04
EP1053023A2 (de) 2000-11-22
WO1999039740A2 (en) 1999-08-12
DE69936444T3 (de) 2012-05-10
WO1999039740A3 (en) 1999-10-28
WO1999039741A2 (en) 1999-08-12
CA2321837C (en) 2011-08-16
JP2002502831A (ja) 2002-01-29
DE69936444T2 (de) 2008-03-20
EP1053023B1 (de) 2007-07-04
CA2321837A1 (en) 1999-08-12
EP1053023B2 (de) 2011-03-30
DE69936444D1 (de) 2007-08-16
WO1999039741A3 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
DE69936444D1 (de) Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie
ATE196844T1 (de) Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
DE69708100D1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
MX9709915A (es) Heterociclos de peptidilo y composiciones que los contienen, utiles en el tratamiento de trastornos relacionados con trombina, y uso de los mismos.
TR199902956T2 (xx) Pozisyonlar 5 ve 6 i�inde de�i�tirilmi� olan GnRH antagonistleri.
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
IL134445A0 (en) A method of preventing or treating estrogen-dependent diseases and disorders
ID21529A (id) Metode dan komposisi untuk pengobatan dan pencegahan tumor, gangguan yang berhubungan dengan tumor dan kakeksia
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
TW362971B (en) Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M-phase specific anti
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
ATE241993T1 (de) Zubereitungen zur tumorbehandlung enthaltend hai- knorpelextrakte und antineoplastische mittel
IL146125A0 (en) Novel quinones as disease therapies
HUP0004326A3 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
BG103832A (en) Leptin as tumour cells proliferation inhibitor
EP0944389A4 (de) Gereinigte zubereitungen von 10-propargyl-10-deazaaminopterin und verfahren zu ihrer verwendung in der tumorbehandlung
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
DE69633178D1 (de) Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
DE69720783D1 (de) Reaktive sauerstoffverbindungen enthaltende verbindungen zur induzierung von zelldifferentiation maligner zellen so wie leukämie
ATE258797T1 (de) Verwendung von amifostin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties